Cargando…

Galectin-3 is Associated with Cardiovascular Events in Post-Acute Coronary Syndrome Patients with Type-2 Diabetes

Introduction: Type-2 diabetes mellitus (T2DM) is associated with early and severe atherosclerosis. However, few biomarkers can predict cardiovascular events in this population. Methods: We followed 964 patients with coronary artery disease (CAD), assessing plasma levels of galectin-3, monocyte chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorenzo-Almorós, Ana, Pello, Ana, Aceña, Álvaro, Martínez-Milla, Juan, González-Lorenzo, Óscar, Tarín, Nieves, Cristóbal, Carmen, Blanco-Colio, Luis M, Martín-Ventura, José Luis, Huelmos, Ana, Gutiérrez-Landaluce, Carlos, López-Castillo, Marta, Kallmeyer, Andrea, Cánovas, Ester, Alonso, Joaquín, López Bescós, Lorenzo, Egido, Jesús, Lorenzo, Óscar, Tuñón, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230213/
https://www.ncbi.nlm.nih.gov/pubmed/32294902
http://dx.doi.org/10.3390/jcm9041105
_version_ 1783534897041768448
author Lorenzo-Almorós, Ana
Pello, Ana
Aceña, Álvaro
Martínez-Milla, Juan
González-Lorenzo, Óscar
Tarín, Nieves
Cristóbal, Carmen
Blanco-Colio, Luis M
Martín-Ventura, José Luis
Huelmos, Ana
Gutiérrez-Landaluce, Carlos
López-Castillo, Marta
Kallmeyer, Andrea
Cánovas, Ester
Alonso, Joaquín
López Bescós, Lorenzo
Egido, Jesús
Lorenzo, Óscar
Tuñón, Jose
author_facet Lorenzo-Almorós, Ana
Pello, Ana
Aceña, Álvaro
Martínez-Milla, Juan
González-Lorenzo, Óscar
Tarín, Nieves
Cristóbal, Carmen
Blanco-Colio, Luis M
Martín-Ventura, José Luis
Huelmos, Ana
Gutiérrez-Landaluce, Carlos
López-Castillo, Marta
Kallmeyer, Andrea
Cánovas, Ester
Alonso, Joaquín
López Bescós, Lorenzo
Egido, Jesús
Lorenzo, Óscar
Tuñón, Jose
author_sort Lorenzo-Almorós, Ana
collection PubMed
description Introduction: Type-2 diabetes mellitus (T2DM) is associated with early and severe atherosclerosis. However, few biomarkers can predict cardiovascular events in this population. Methods: We followed 964 patients with coronary artery disease (CAD), assessing plasma levels of galectin-3, monocyte chemoattractant protein-1 (MCP-1), and N-terminal fragment of brain natriuretic peptide (NT-proBNP) at baseline. The secondary outcomes were acute ischemia and heart failure or death. The primary outcome was the combination of the secondary outcomes. Results. Two hundred thirty-two patients had T2DM. Patients with T2DM showed higher MCP-1 (144 (113–195) vs. 133 (105–173) pg/mL, p = 0.006) and galectin-3 (8.3 (6.5–10.5) vs. 7.8 (5.9–9.8) ng/mL, p = 0.049) levels as compared to patients without diabetes. Median follow-up was 5.39 years (2.81–6.92). Galectin-3 levels were associated with increased risk of the primary outcome in T2DM patients (Hazard ratio (HR) 1.57 (1.07–2.30); p = 0.022), along with a history of cerebrovascular events. Treatment with clopidogrel was associated with lower risk. In contrast, NT-proBNP and MCP-1, but not galectin-3, were related to increased risk of the event in nondiabetic patients (HR 1.21 (1.04–1.42); p = 0.017 and HR 1.23 (1.05–1.44); p = 0.012, respectively), along with male sex and age. Galectin-3 was also the only biomarker associated with the development of acute ischemic events and heart failure or death in T2DM patients, while, in nondiabetics, MCP-1 and NT-proBNP, respectively, were related to these events. Conclusion: In CAD patients, galectin-3 plasma levels are associated with cardiovascular events in patients with T2DM, and MCP-1 and NT-proBNP in those without T2DM.
format Online
Article
Text
id pubmed-7230213
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72302132020-05-28 Galectin-3 is Associated with Cardiovascular Events in Post-Acute Coronary Syndrome Patients with Type-2 Diabetes Lorenzo-Almorós, Ana Pello, Ana Aceña, Álvaro Martínez-Milla, Juan González-Lorenzo, Óscar Tarín, Nieves Cristóbal, Carmen Blanco-Colio, Luis M Martín-Ventura, José Luis Huelmos, Ana Gutiérrez-Landaluce, Carlos López-Castillo, Marta Kallmeyer, Andrea Cánovas, Ester Alonso, Joaquín López Bescós, Lorenzo Egido, Jesús Lorenzo, Óscar Tuñón, Jose J Clin Med Article Introduction: Type-2 diabetes mellitus (T2DM) is associated with early and severe atherosclerosis. However, few biomarkers can predict cardiovascular events in this population. Methods: We followed 964 patients with coronary artery disease (CAD), assessing plasma levels of galectin-3, monocyte chemoattractant protein-1 (MCP-1), and N-terminal fragment of brain natriuretic peptide (NT-proBNP) at baseline. The secondary outcomes were acute ischemia and heart failure or death. The primary outcome was the combination of the secondary outcomes. Results. Two hundred thirty-two patients had T2DM. Patients with T2DM showed higher MCP-1 (144 (113–195) vs. 133 (105–173) pg/mL, p = 0.006) and galectin-3 (8.3 (6.5–10.5) vs. 7.8 (5.9–9.8) ng/mL, p = 0.049) levels as compared to patients without diabetes. Median follow-up was 5.39 years (2.81–6.92). Galectin-3 levels were associated with increased risk of the primary outcome in T2DM patients (Hazard ratio (HR) 1.57 (1.07–2.30); p = 0.022), along with a history of cerebrovascular events. Treatment with clopidogrel was associated with lower risk. In contrast, NT-proBNP and MCP-1, but not galectin-3, were related to increased risk of the event in nondiabetic patients (HR 1.21 (1.04–1.42); p = 0.017 and HR 1.23 (1.05–1.44); p = 0.012, respectively), along with male sex and age. Galectin-3 was also the only biomarker associated with the development of acute ischemic events and heart failure or death in T2DM patients, while, in nondiabetics, MCP-1 and NT-proBNP, respectively, were related to these events. Conclusion: In CAD patients, galectin-3 plasma levels are associated with cardiovascular events in patients with T2DM, and MCP-1 and NT-proBNP in those without T2DM. MDPI 2020-04-13 /pmc/articles/PMC7230213/ /pubmed/32294902 http://dx.doi.org/10.3390/jcm9041105 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lorenzo-Almorós, Ana
Pello, Ana
Aceña, Álvaro
Martínez-Milla, Juan
González-Lorenzo, Óscar
Tarín, Nieves
Cristóbal, Carmen
Blanco-Colio, Luis M
Martín-Ventura, José Luis
Huelmos, Ana
Gutiérrez-Landaluce, Carlos
López-Castillo, Marta
Kallmeyer, Andrea
Cánovas, Ester
Alonso, Joaquín
López Bescós, Lorenzo
Egido, Jesús
Lorenzo, Óscar
Tuñón, Jose
Galectin-3 is Associated with Cardiovascular Events in Post-Acute Coronary Syndrome Patients with Type-2 Diabetes
title Galectin-3 is Associated with Cardiovascular Events in Post-Acute Coronary Syndrome Patients with Type-2 Diabetes
title_full Galectin-3 is Associated with Cardiovascular Events in Post-Acute Coronary Syndrome Patients with Type-2 Diabetes
title_fullStr Galectin-3 is Associated with Cardiovascular Events in Post-Acute Coronary Syndrome Patients with Type-2 Diabetes
title_full_unstemmed Galectin-3 is Associated with Cardiovascular Events in Post-Acute Coronary Syndrome Patients with Type-2 Diabetes
title_short Galectin-3 is Associated with Cardiovascular Events in Post-Acute Coronary Syndrome Patients with Type-2 Diabetes
title_sort galectin-3 is associated with cardiovascular events in post-acute coronary syndrome patients with type-2 diabetes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230213/
https://www.ncbi.nlm.nih.gov/pubmed/32294902
http://dx.doi.org/10.3390/jcm9041105
work_keys_str_mv AT lorenzoalmorosana galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT pelloana galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT acenaalvaro galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT martinezmillajuan galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT gonzalezlorenzooscar galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT tarinnieves galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT cristobalcarmen galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT blancocolioluism galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT martinventurajoseluis galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT huelmosana galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT gutierrezlandalucecarlos galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT lopezcastillomarta galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT kallmeyerandrea galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT canovasester galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT alonsojoaquin galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT lopezbescoslorenzo galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT egidojesus galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT lorenzooscar galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes
AT tunonjose galectin3isassociatedwithcardiovasculareventsinpostacutecoronarysyndromepatientswithtype2diabetes